Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Amyloid Fibrils03:03

Amyloid Fibrils

12.4K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Amyloid Fibrils03:03

Amyloid Fibrils

6.8K
6.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Seizures: Classification01:13

Seizures: Classification

1.9K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of Suppression of Large-Radius Jets and Its Dependence on Substructure in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2023
Same author

Measurement of the Sensitivity of Two-Particle Correlations in pp Collisions to the Presence of Hard Scatterings.

Physical review letters·2023
Same author

Observation of the γγ→ττ Process in Pb+Pb Collisions and Constraints on the τ-Lepton Anomalous Magnetic Moment with the ATLAS Detector.

Physical review letters·2023
Same author

Observation of an Excess of Dicharmonium Events in the Four-Muon Final State with the ATLAS Detector.

Physical review letters·2023
Same author

Arerugi = [Allergy]·2023
Same author

Strong Constraints on Jet Quenching in Centrality-Dependent p+Pb Collisions at 5.02 TeV from ATLAS.

Physical review letters·2023
Same journal

Familial pulmonary fibrosis due to pathogenic TERT variant presenting with a UIP-PPFE phenotype.

QJM : monthly journal of the Association of Physicians·2026
Same journal

Corkscrew Oesophagus Due to Distal Oesophageal Spasm.

QJM : monthly journal of the Association of Physicians·2026
Same journal

Correction to: Integrated care management for patients following acute stroke: a systematic review.

QJM : monthly journal of the Association of Physicians·2026
Same journal

Methodological concerns regarding blinding and long term efficacy of fire needle therapy for plaque psoriasis.

QJM : monthly journal of the Association of Physicians·2026
Same journal

Media framing of GLP-1/GIP therapies in Japan: Lessons for aging universal health coverage systems.

QJM : monthly journal of the Association of Physicians·2026
Same journal

Regional heterogeneity in psoriasis area and severity index response to fire needle therapy for plaque psoriasis.

QJM : monthly journal of the Association of Physicians·2026
See all related articles

Related Experiment Video

Updated: Mar 5, 2026

Prion Safety Laboratory Swipe Test
06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

1.4K

Creutzfeld Jacob disease

A Markel1,2, O Monich1, E Bar-Meir2,3

  • 1From the Department of Internal Medicine A, Haemek Medical Center, Afula.

QJM : Monthly Journal of the Association of Physicians
|March 25, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material
09:50

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Published on: September 29, 2017

14.5K
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
11:29

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain

Published on: October 3, 2012

11.3K

Related Experiment Videos

Last Updated: Mar 5, 2026

Prion Safety Laboratory Swipe Test
06:01

Prion Safety Laboratory Swipe Test

Published on: February 14, 2025

1.4K
Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material
09:50

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Published on: September 29, 2017

14.5K
Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
11:29

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain

Published on: October 3, 2012

11.3K